Prognosis of pN3 Stage Gastric Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose : The aim of this study was to determine the prognosis of pN3 stage gastric cancer patients after they have undergone curative resection, and we also wanted to identify the prognostic factors according to the clinico-pathologic features. Materials and Methods : Between January 2000 and December 2004, we retrospectively reviewed the medical records of the patients with histologically confirmed pN3 stage gastric cancer. They underwent both gastrectomy and lymphadenectomy with a curative aim. We categorized the pN3 stage patients into 2 groups; one with pN3 only (pN3M0) and the other with pN3 combined with M1 stage (pN3M1) that included peritoneal seeding, hepatic metastasis or para-aortic LN metastasis. Results : Out of 467 patients with stage IV gastric adenocarcinoma who received surgery, 260 patients underwent curative resection and they were pathologically staged as N3. Among these 260 patients, 78 patients were classified as the pN3/M1 stage. For all the patients, the median follow-up period was 19 months (range: 1~108 months) and the median overall survival time was 16.2 months (95% CI, 14.1~18.3%). The 5-year survival rate of the pN3/M0 group was significantly higher than that of the pN3/M1 group (12.6% vs. 2.6%, respectively, p=0.0001). The identified predictor for a worse prognosis was an advanced T4 stage (HR: 3.38, 95% CI, 1.4~8.3, p=0.008) for the pN3 patients. Conclusion : The survival for the pN3 gastric cancer patients after curative gastrectomy was significantly longer in the pN3/M0 group as compared to that of the pN3/M1 group. An advanced T stage was a predictor for a poor prognosis for the pN3 patients. Therefore, diverse treatment strategies for these heterogeneous pN3 gastric cancer patients are needed for improving their survival.
Abstract
Purpose : The aim of this study was to determine the prognosis of pN3 stage gastric cancer patients after they have undergone curative resection, and we also wanted to identify the prognostic factors according to the clinico-pathologic features. Materials and Methods : Between January 2000 and December 2004, we retrospectively reviewed the medical records of the patients with histologically confirmed pN3 stage gastric cancer. They underwent both gastrectomy and lymphadenectomy with a curative aim. We categorized the pN3 stage patients into 2 groups; one with pN3 only (pN3M0) and the other with pN3 combined with M1 stage (pN3M1) that included peritoneal seeding, hepatic metastasis or para-aortic LN metastasis. Results : Out of 467 patients with stage IV gastric adenocarcinoma who received surgery, 260 patients underwent curative resection and they were pathologically staged as N3. Among these 260 patients, 78 patients were classified as the pN3/M1 stage. For all the patients, the median follow-up period was 19 months (range: 1~108 months) and the median overall survival time was 16.2 months (95% CI, 14.1~18.3%). The 5-year survival rate of the pN3/M0 group was significantly higher than that of the pN3/M1 group (12.6% vs. 2.6%, respectively, p=0.0001). The identified predictor for a worse prognosis was an advanced T4 stage (HR: 3.38, 95% CI, 1.4~8.3, p=0.008) for the pN3 patients. Conclusion : The survival for the pN3 gastric cancer patients after curative gastrectomy was significantly longer in the pN3/M0 group as compared to that of the pN3/M1 group. An advanced T stage was a predictor for a poor prognosis for the pN3 patients. Therefore, diverse treatment strategies for these heterogeneous pN3 gastric cancer patients are needed for improving their survival.
참고문헌 (19)
- Kamangar F, "Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world", J Clin Oncol, 24, pp.2137~2150 (2006)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Jemal A, "Cancer statistics, 2008", CA Cancer J Clin, 58, pp.71~96 (2008)
- Hartgrink HH, "Value of palliative resection in gastric cancer", Br J Surg, 89, pp.1438~1443 (2002)
- Klein Kranenbarg E, "Evaluation of the 5th edition of the TNM classification for gastric cancer: improved prognostic value", Br J Cancer, 84, pp.64~71 (2001)
- Medina-Franco H, "Surgery for stage IV gastric cancer", Am J Surg, 187, pp.543~546 (2004)
- Park JM, "pN3M0 gastric cancer: the category that allows the sub-classification of stage-IV gastric cancer (IVa and IVb)", Ann Surg Oncol, 14, pp.2535~2542 (2007)
- Catalano V, "Gastric cancer", Crit Rev Oncol Hematol, 1287, pp.1~38 (2009)
- Japanese Gastric Cancer Association, "Japanese Classification of Gastric Carcinoma - 2nd English Edition", Gastric Cancer, 1, pp.10~24 (1998)
- Takeno S, "Analysis of the survival period in resectable stage IV gastric cancer", Ann Surg Oncol, 8, pp.215~221 (2001)
- Lim S, "Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups?", J Surg Oncol, 95, pp.118~122 (2007)
- Yoo CH, "Comparison of prognostic significance of nodal staging between old (4th edition) and new (5th edition) UICC TNM classification for gastric carcinoma. International Union Against Cancer", World J Surg, 23, pp.492~497 (1999)
- Lin SZ, "Palliative gastrectomy and chemotherapy for stage IV gastric cancer", J Cancer Res Clin Oncol, 134, pp.187~192 (2008)
- Li C, "Prognostic influence of sub-stages according to pTNM categories in patients with stage IV gastric cancer", J Surg Oncol, 99, pp.324~328 (2009)
- An JY, "Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM", Arch Surg, 144, pp.38~45 (2009)
- An JY, "Borrmann type IV: an independent prognostic factor for survival in gastric cancer", J Gastrointest Surg, 12, pp.1364~1369 (2008)
- Jeong Hwan Yook, "Clinicopathological Analysis of Borrmann Type IV Gastric Cancer", Cancer Research and Treatment, 37(2), pp.87~91 (2005), 대한암학회
- Kunisaki C, "Tumor diameter as a prognostic factor in patients with gastric cancer", Ann Surg Oncol, 15, pp.1959~1967 (2008)
- Sakuramoto S, "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine", N Engl J Med, 357, pp.1810~1820 (2007)